Last Updated: October 15th, 2025
To succeed across markets, pipeline assets require a well-informed global pricing strategy. By effectively combining technical ability with practical agility, teams can not only optimize pricing but also anticipate HTA challenges and strengthen reimbursement positioning.
What Is Global Price Targeting for a Pipeline Asset?
Global price targeting involves early defining price expectations and reimbursement pathways by assessing competitor analogs, payer needs, market access landscapes, and economic modeling. As a result, it helps pharma/biotech companies plan launch strategies that are commercially viable and compliant with multiple jurisdictions.
How Our Technology Delivers Results
Our expertise in Technical Ability includes:
- Literature review & secondary research: Deep dive into European HTA pathways, pricing databases, and comparative analog analyses.
- CEM strategic recommendations: Leveraging guidelines (e.g. NICE DSU), analog insights, HTA requirements, and economic modeling to optimize structure and assumptions.
- Primary research: Conducting stakeholder interviews across the EU-5 to validate insights and modeling, understand burden, and identify target pricing estimates.
How Our Practical Agility Keeps Teams Ahead
Under Practical Agility, what we offer:
- CEM recommendations were applied to shape evidence generation strategies, ensuring relevance in both CE and non-CE markets.
- Developed graphical landscape decks to communicate treatment approaches, competitive context, and reimbursement environments.
- Delivered pricing & market access reports that guided payer positioning and highlighted population or evidence gaps.
Why This Matters for Pipeline Assets
Early alignment on pricing and reimbursement strategy reduces surprise risks at HTA review, while clear, evidence-backed pricing positions support payer negotiations and market access. Additionally, a good balance of ability and agility ensures the strategy remains relevant as clinical data or market conditions evolve.
Customer Testimonies
A Step Forward in Pipeline Pricing Strategy
Developing a global price targeting framework that combines Technical Ability with Practical Agility not only helps pharma and biotech companies navigate complex reimbursement landscapes but also enables them to launch confidently. Moreover, by engaging stakeholders early, validating assumptions, and staying nimble, teams can effectively define and adapt pricing strategies that consistently maximize access and value.
Is your pricing strategy launch-ready?
Meet our Modeling Team
Dawn Lee
Strategic Council member
Dawn is a highly experienced health economic modeler with over 50 submissions to the UK Health Technology Assessment. She has worked across more than 30 countries globally and is a member of NICE’s interventional procedures advisory committee and the R for HTA group. Dawn is particularly focused on oncology modeling, immune-oncology, and flexible survival modeling. She also provides training on NICE processes and regularly represents clients at Committee meetings.
Holly Guy
Executive Director
She has extensive experience in HEOR consulting across the product lifecycle and numerous disease areas, including haematology, thrombosis, oncology, infectious diseases, and gastroenterology. She has over 30 successful HTA submissions, including those to NICE, SMC, and AWMSG in the UK, as well as in several European countries. She has attended and represented pharma companies at NICE and AWMSG appraisal committee meetings. She led the team that helped secure regulatory approval for treatment targeting advanced ovarian cancer, marking the first new product to reach the market in nearly 20 years.
Vicki Laskier
Director
Vicki specializes in the strategy and implementation of HEOR solutions. With extensive experience in developing HTA dossiers, systematic literature reviews, and economic models, she has contributed to over 19 HTA submissions across NICE, SMC, and NCPE. Vicki has also represented companies at HTA meetings, leading the development of tools that support both payer and internal needs. Her work in statistical analysis, including Bayesian methods and network meta-regressions, has been widely used in healthcare decision-making.
FAQs on Global Price Targeting
- What is global price targeting, and when should it start?
It’s defining pricing expectations ahead of launch. It’s ideal to start during the late preclinical to early clinical phases to steer development strategy and reimbursement planning. - What resources are needed?
Access to market data, analog product performance, payer pathway guidelines, modeling expertise, stakeholder networks. - How is agility maintained as new data emerges?
By iterative modeling, regular reviews, maintaining flexible assumptions, and adapting strategies to new clinical or regulatory information. - What are typical deliverables?
Examples include landscape assessment decks, pricing & access reports, strategic recommendations, and evidence generation planning.